Banophen Oral Solution, Sugar Free, Alcohol Free, Cherry Flavor, (Diphenhydramine HCl, USP) Each ...
FDA Drug Recall #D-1352-2019 — Class II — May 21, 2019
Recall Summary
| Recall Number | D-1352-2019 |
| Classification | Class II — Moderate risk |
| Date Initiated | May 21, 2019 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Torrent Pharma Inc |
| Location | Levittown, PA |
| Product Type | Drugs |
| Quantity | 655,104 bottles |
Product Description
Banophen Oral Solution, Sugar Free, Alcohol Free, Cherry Flavor, (Diphenhydramine HCl, USP) Each teaspoonful contains diphenhydramine hydrochloride, USP 12.5 mg, a) 4 Fl. oz. (118 mL) bottle, NDC: 0904-1228-00, b) One Pint (473 mL) bottle, NDC: 0904-5174-16, Distributed by Major Pharmaceuticals, Livonia MI 48152.
Reason for Recall
cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).
Distribution Pattern
Product was distributed to 9 distributors, direct accounts and relabelers who may have further distributed the product throughout the United States.
Lot / Code Information
Lot #s: a)17E018; 17E020, 17E026, Exp. 05/2019; 17H008; 17H018; 17H028, Exp. 08/2019; 17J002; 17J025; 17J028, Exp. 09/2019; 17L035, Exp. 11/2019; 17M024, Exp. 12/2019; 18A017, Exp. 01/2020; 18B016, Exp. 02/2020; 18C011, Exp. 03/2020; 18D014; 18D021; 18D026, Exp. 04/2020; 18E014, Exp. 05/2020; 18F036, Exp. 06/2020; 18F035; 18G018, Exp. 07/2020; 18H005; 18H015, Exp. 08/2020; 19A011; 19A013, Exp. 01/2121. b) 17E013; 17E025; 17E028; 17E041, Exp. 05/2019; 17F009; 17F016, Exp. 06/2019; 17G007; 17G021; 17G032, Exp. 07/2019; 17H023, Exp. 08/2019; 17J001; 17J012; 17J023; 17J027, Exp. 09/2019; 17K004; 17K022; 17K028; 17K028A, Exp. 10/2019; 17L032; Exp. 11/2019; 17M036, Exp. 12/2019; 18A011; 18A019; 18A030; 18A032; 18A041, Exp. 01/2020; 18B010; 18B038, Exp. 02/2020; 18C008; 18C022; 18C030, Exp. 03/2020; 18D004; 18D008; 18D010; 18D011, Exp. 04/2020; 18F028; 18H010, Exp. 06/2020; 18G004; 18G012, Exp. 07/2020; 18H002; 18H011; 18H027; 18H032; 18H033, Exp. 08/2020; 18K008; 18K009, Exp. 10/2020.
Other Recalls from Torrent Pharma Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0852-2022 | Class II | Pantoprazole Sodium Delayed-Release Tablets, US... | Apr 11, 2022 |
| D-0166-2021 | Class I | Anagrelide Capsules, USP 1 mg, 100 capsules, Rx... | Nov 25, 2020 |
| D-1371-2019 | Class II | Nasal Decongestant Liquid, Pseudoephedrine HCl,... | May 21, 2019 |
| D-1367-2019 | Class II | Kid Kare Childrens Cough/Cold Liquid, Antihista... | May 21, 2019 |
| D-1357-2019 | Class II | Biscolax Laxative (Bisacodyl, USP 10 mg), a) 12... | May 21, 2019 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.